Global Migraine Market Analysis

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Migraine Market Analysis

  • Pharmaceutical
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

In recent years, the migraine market is anticipated to grow rapidly during the forecast period. Migraine is the world's 19th most prevalent cause of disability, according to the World Health Organization. Migraine sufferers take twice as many prescription drugs and visit doctors and emergency rooms twice as often as individuals who do not suffer from the condition. Migraine sufferers have also spent significantly more on healthcare. Migraine sufferers are observed to consume 2.5 times as many prescription drugs and have six times the number of diagnostic tests and services as non-migraine sufferers. As a result of the rising occurrence of migraine, more therapies are being used to provide relief, which serves to drive the entire market.

Filled Map Analysis

Frequently Asked Questions

The market is segmented based on Segmentation, By Types (Episodic, Chronic), Symptoms (Food Cravings, Depression, Fatigue, Frequent Yawning, Hyperactivity, Irritability, Neck Stiffness, Others), Treatment (Medication, Acupressure, Counseling, Hormone Therapy, Others), Diagnosis (Computerized Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032 .
The Global Migraine Market size was valued at USD 3.95 USD Billion in 2024.
The Global Migraine Market is projected to grow at a CAGR of 4.1% during the forecast period of 2025 to 2032.
The major players operating in the market include ,F. Hoffmann-La Roche Ltd. Mylan N.V. Teva Pharmaceutical Industries Ltd.Sanofi Pfizer Inc. GlaxoSmithKline plc Novartis AG Bayer AG Eli Lilly and Company Merck &amp, Co.Inc. Allergan AstraZeneca AbbVie Inc. WOCKHARDT Johnson &amp, Johnson Private Limited Cipla Inc. Amneal Pharmaceuticals LLC. Eisai Co.Ltd. Bausch Health Companies Inc. Abbott Takeda Pharmaceutical Company Limited Merck KGaA ,.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.